Last updated: August 28, 2026
Flutamide is a mature, low-cost generic antiandrogen with limited commercial growth potential. The drug was approved in the United States in 1989 for metastatic prostate cancer and has lost originator exclusivity. Its market has contracted as physicians shifted toward bicalutamide, abiraterone, enzalutamide, apalutamide, and darolutamide. Current demand is sustained primarily by low acquisition cost, clinical familiarity, and use in selected androgen-deprivation regimens rather than by innovation or pricing power.
What is the current market position of flutamide?
Flutamide is a nonsteroidal androgen-receptor antagonist. It is administered with medical or surgical castration to treat metastatic prostate cancer. The FDA-approved U.S. dosage is 250 mg three times daily, generally delivered as 125 mg capsules or tablets.[1]
The product has three commercial characteristics:
| Factor |
Market effect |
| Generic availability |
Eliminates most originator pricing power |
| Hepatotoxicity risk |
Limits use and increases monitoring costs |
| Older mechanism and dosing |
Reduces competitiveness against newer oral androgen-receptor inhibitors |
| Low manufacturing complexity |
Supports multiple generic supply sources |
| No meaningful exclusivity |
Prevents premium pricing or protected market expansion |
Flutamide remains commercially available in the United States, but it occupies a small and declining niche in prostate-cancer pharmacotherapy. Its principal economic value is as a low-cost generic, not as a branded oncology product.
When did flutamide lose exclusivity?
Flutamide lost practical U.S. market exclusivity years ago. The branded product Eulexin was developed by Schering-Plough and approved by the FDA in 1989. The active ingredient and core product rights are now associated with an off-patent generic market.[1][2]
Flutamide exclusivity timeline
| Event |
Approximate date |
Commercial significance |
| FDA approval of Eulexin |
1989 |
Originator launch for metastatic prostate cancer |
| Generic approvals |
1990s onward |
Beginning of price and share erosion |
| Originator consolidation through Schering-Plough/Merck |
2009 |
Eulexin became part of a broader legacy portfolio |
| Broad availability of generic flutamide |
2000s |
Originator differentiation largely disappeared |
| Current market |
2020s |
Mature generic product with low pricing power |
No current U.S. regulatory exclusivity is associated with flutamide as an active ingredient. The drug has no biologic exclusivity period and does not face biosimilar competition because it is a small-molecule product.
What patents protect flutamide?
No commercially significant active U.S. patent estate is generally associated with flutamide today. The relevant composition-of-matter and originator-product protections expired before the current generic market formed.
Patent categories
| Patent category |
Current commercial relevance |
| Flutamide composition of matter |
Expired |
| Original oral formulation |
Expired or no longer commercially significant |
| Dosing and prostate-cancer treatment methods |
Any legacy protection is not a material barrier to generic use |
| Manufacturing process patents |
Potentially relevant to individual suppliers, but not a market-wide barrier |
| Formulation patents |
No widely recognized active U.S. formulation estate supporting premium pricing |
| Pediatric or new-use exclusivity |
Not a current market driver |
The Orange Book is the principal FDA source for listed patents and exclusivity associated with approved drug products.[2] Flutamide’s commercial position does not depend on an active Orange Book patent portfolio. Generic applicants therefore compete mainly on abbreviated new drug application approval, manufacturing reliability, procurement contracts, and price.
Are there Paragraph IV challenges to flutamide?
Paragraph IV litigation is not a current material feature of the flutamide market. The commercial opportunity is too mature and the expected branded-generic price differential is too small to support major patent challenges. Generic entry occurred after the relevant originator protections had expired or ceased to provide an effective market barrier.
What is the FDA regulatory status of flutamide?
Flutamide remains an FDA-approved prescription drug, but its label carries a prominent hepatotoxicity warning. Severe liver injury, including hospitalization and death, has been reported. The FDA labeling recommends liver-function testing before treatment and during the first four months of therapy, with additional testing when clinically indicated.[1]
Regulatory risk
The main regulatory issue is safety rather than approval status.
| Regulatory issue |
Effect on market |
| Severe hepatotoxicity |
Reduces physician willingness to use flutamide |
| Need for liver-function monitoring |
Adds clinical and administrative burden |
| Availability of alternatives |
Makes risk-benefit comparisons less favorable |
| No new indication strategy |
Limits regulatory-driven growth |
Flutamide remains an approved option, but the safety profile has weakened its position relative to bicalutamide and newer androgen-receptor pathway agents.
What formulations are protected by flutamide patents?
Flutamide is commercially available primarily as an immediate-release oral dosage form, commonly in 125 mg strength. The approved regimen requires three daily doses, producing a higher pill burden than many newer therapies.[1]
There is no major active formulation franchise comparable to extended-release, depot, transdermal, or long-acting injectable products. This limits lifecycle-management opportunities.
Formulation economics
The immediate-release formulation has low technical barriers:
- Conventional oral manufacturing
- Widely available active pharmaceutical ingredient
- No complex delivery device
- No sterile production requirement
- No cold-chain requirement
- No specialized administration infrastructure
Manufacturers can compete through scale, quality compliance, supply continuity, and wholesaler access. A supplier with an approved facility and reliable API sourcing can generally participate without overcoming a high formulation barrier.
How does flutamide compare with competing prostate-cancer drugs?
Flutamide competes across different treatment generations. Older antiandrogens remain inexpensive, while newer agents command substantially higher prices because they offer stronger clinical positioning, improved dosing convenience, or broader use in advanced disease.
| Drug |
Mechanism or class |
Market position |
Key commercial advantage |
| Flutamide |
First-generation nonsteroidal antiandrogen |
Mature generic |
Low cost |
| Bicalutamide |
First-generation nonsteroidal antiandrogen |
Generic standard in many settings |
Once-daily dosing and better tolerability profile |
| Nilutamide |
First-generation antiandrogen |
Limited niche |
Generic availability |
| Abiraterone |
Androgen biosynthesis inhibitor |
Generic and branded versions |
Strong clinical adoption in combination regimens |
| Enzalutamide |
Second-generation androgen-receptor inhibitor |
Branded and increasingly generic competition |
Efficacy and established treatment guidelines |
| Apalutamide |
Second-generation androgen-receptor inhibitor |
Branded |
Use in nonmetastatic and metastatic castration-sensitive disease |
| Darolutamide |
Second-generation androgen-receptor inhibitor |
Branded |
Differentiated safety and combination positioning |
Bicalutamide is the closest direct pharmacologic competitor. Its once-daily administration and generally more favorable clinical acceptance have displaced much of flutamide’s use. Enzalutamide and other next-generation agents compete less on price and more on outcomes, disease setting, and guideline preference.
What is the financial trajectory for flutamide?
Flutamide has moved through the standard branded-to-generic pharmaceutical revenue cycle:
- Originator revenue during the Eulexin period.
- Generic entry and rapid price compression.
- Declining unit economics as competitors entered.
- Stable but low-value demand from a residual clinical niche.
- Ongoing exposure to procurement pricing and supply volatility.
Public companies do not generally report flutamide revenue as a separate line item. It is typically included within broader generic-pharmaceutical revenue. As a result, a reliable current global revenue figure or product-level margin estimate is not publicly established.
Financial trajectory by period
| Period |
Revenue profile |
Margin profile |
Primary driver |
| 1989 to early 1990s |
Branded oncology revenue |
High relative margin |
Originator exclusivity |
| 1990s to 2000s |
Rapid erosion |
Declining margin |
Generic entry |
| 2010s |
Low, fragmented generic revenue |
Low to moderate |
Commodity competition |
| 2020s |
Stable residual demand |
Low and procurement-sensitive |
Clinical niche and supply availability |
The financial opportunity is concentrated in operational efficiency rather than market expansion. Potential value comes from:
- Low-cost API procurement
- High manufacturing utilization
- Reliable supply to wholesalers and hospitals
- Contract manufacturing
- Regional registrations
- Portfolio bundling with other generic oncology products
The product is unlikely to support meaningful standalone revenue growth without a new formulation, a new indication, or a major supply disruption affecting competitors.
Which companies are challenging flutamide?
No major branded company is pursuing an active commercial challenge centered on flutamide. Competition is primarily among generic manufacturers and distributors. Market participants may change by country and over time because product ownership, national marketing authorizations, and supply contracts shift frequently.
The competitive structure is fragmented:
- Generic pharmaceutical companies compete on tender price and availability.
- Contract manufacturers supply API or finished dosage forms.
- Regional distributors control access in lower-volume markets.
- Branded oncology companies compete indirectly through newer therapies.
The absence of a dominant branded franchise reduces the likelihood of significant promotional spending. Flutamide demand is generally generated by formularies, prescribing habits, clinical protocols, and price.
What licensing deals affect flutamide?
There is no major current licensing transaction that materially changes the commercial outlook for flutamide. Historical rights were connected to the originator product and corporate transactions involving Schering-Plough and Merck. Those transactions did not create a current premium franchise.
Licensing economics are limited because:
- The active ingredient is generic.
- There is no major proprietary delivery system.
- There is no established companion diagnostic.
- The clinical market is mature.
- Competing therapies have stronger commercial differentiation.
A current transaction would more likely involve manufacturing, regional distribution, or portfolio acquisition than an exclusive global license.
What patent litigation affects flutamide?
No active, high-value U.S. patent litigation is a central factor in the flutamide market. The product is not comparable to a recently approved oncology drug facing Paragraph IV challenges, patent-term adjustments, or settlement-driven generic-entry dates.
Litigation risk may still arise from ordinary generic-sector issues, including:
- Manufacturing quality disputes
- Product liability claims involving liver injury
- Regulatory enforcement
- Supply-contract disputes
- Trademark or labeling issues
- Foreign patent or registration disputes
These issues do not create a meaningful barrier to generic market participation at the active-ingredient level.
What generic entry risks exist for flutamide?
Generic entry risk is largely historical because generic products already occupy the market. The relevant business risks now concern further price erosion and supply competition.
Commercial risks
| Risk |
Likely effect |
| Additional generic suppliers |
Lower prices and reduced volume per supplier |
| API concentration |
Potential shortages or cost increases |
| FDA manufacturing observations |
Product suspension or delayed supply |
| Low demand |
Reduced production incentives |
| Physician substitution |
Continued migration to bicalutamide or newer agents |
| Safety concerns |
Further decline in prescribing |
| Reimbursement controls |
Lower net realized prices |
The largest risk for an individual manufacturer is not market entry by a first generic. It is loss of volume after additional suppliers enter or after a wholesaler changes its preferred-source strategy.
How strong is the flutamide patent estate?
The flutamide patent estate is weak for commercial purposes. It does not provide a defensible U.S. exclusivity position, support premium pricing, or block ordinary generic competition.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Active Orange Book leverage |
Limited or absent |
| Formulation differentiation |
Weak |
| Method-of-use protection |
Not a material market barrier |
| Manufacturing barriers |
Low to moderate, depending on supplier |
| Litigation leverage |
Low |
| Lifecycle-management potential |
Low |
Geographic conditions differ. Some countries may retain local registration rights, formulation claims, or regulatory barriers, but those protections do not recreate a global premium market. The strongest practical barriers are regulatory compliance, local authorization, distribution access, and manufacturing quality.
What is the outlook for flutamide revenue?
The base-case outlook is flat to declining revenue in nominal terms, with continued volume persistence in selected markets. Unit prices are likely to remain under pressure, while occasional supply constraints may produce short-term price increases for individual suppliers.
Base-case outlook
- No meaningful return of branded pricing.
- Continued generic availability.
- Declining use in markets with broad access to modern androgen-receptor inhibitors.
- Residual demand in cost-sensitive health systems.
- Limited product-level investment.
- Low probability of material revenue growth without a differentiated reformulation.
Flutamide may retain value as a portfolio product for a generic manufacturer with existing oncology distribution. It is less attractive as a standalone acquisition or licensing target.
Key Takeaways
- Flutamide is a mature generic antiandrogen approved in the U.S. in 1989.
- The product has no meaningful current U.S. exclusivity or patent-based pricing protection.
- Its principal commercial weakness is hepatotoxicity combined with three-times-daily dosing.
- Bicalutamide is the closest generic competitor; newer agents compete through stronger clinical positioning.
- Public companies generally do not disclose flutamide revenue separately.
- Financial performance is driven by manufacturing cost, supply reliability, and procurement access.
- Paragraph IV litigation, biosimilar risk, and active originator patent litigation are not material current drivers.
- The market outlook is stable to declining, with residual demand in cost-sensitive and legacy-treatment settings.
FAQs About Flutamide Market and Commercial Outlook
Is flutamide still sold in the United States?
Yes. FDA-approved generic flutamide remains commercially available, primarily in oral 125 mg dosage forms, although product availability can vary by manufacturer and wholesaler.[1]
Is flutamide more profitable than bicalutamide?
Generally no. Both are mature generics, but bicalutamide has broader clinical acceptance and more convenient dosing. Flutamide’s lower demand and safety concerns limit its pricing and margin potential.
Can a company obtain a new patent for flutamide?
A company could seek protection for a genuinely novel formulation, manufacturing process, or therapeutic use, but a new patent would need to satisfy patentability requirements. It would not restore exclusivity to the old active ingredient itself.
Does flutamide have biosimilar competition?
No. Flutamide is a chemically synthesized small molecule, so competitors enter through generic drug applications rather than the FDA biosimilar pathway.
Is flutamide an attractive pharmaceutical acquisition target?
It is generally attractive only as part of a broader generic oncology portfolio. Its low price, limited differentiation, safety liability, and weak patent estate make it unattractive as a standalone growth asset.
References
-
U.S. Food and Drug Administration. (2022). Flutamide prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Prostate cancer. https://www.nccn.org/guidelines
-
National Cancer Institute. (2024). Cancer drug information: Flutamide. https://www.cancer.gov/about-cancer/treatment/drugs/flutamide
-
U.S. Food and Drug Administration. (1989). FDA approval history for Eulexin and flutamide products. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
